Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 176-179

  Butterfield, Jill M ^a   Lodise, Thomas P ^a   Beegle, Scott ^b   Rosen, Jonathan ^b   Farkas, Joshua ^b   Pai, Manjunath P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

lactams; Continuous infusions; Monte carlo simulation; Prolonged infusions

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG CLEARANCE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS;

CONTINUOUS INFUSIONS; MONTE CARLO SIMULATION; PROLONGED INFUSIONS; Β-LACTAMS;

ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SERUM; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890390809     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt300     Document Type: Article

References (16)

1. Rogers GB, Carroll MP, Serisier DJ et al. Bacterial activity in cystic fibrosis lung infections. Respir Res 2005; 6: 49.
2. Cystic Fibrosis Foundation Patient Registry. 2011 Annual Data Report. Bethesda: MD, 2012.
3. Yankaskas JR, Marshall BC, Sufian B et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125 Suppl: 1S-39S.
4. SICOR Pharmaceuticals Inc. Package Literature for Tobramycin. June 2005.
5. Lodise TP Jr, Lomaestro B, Rodvold KA et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004; 48: 4718-24.
6. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on b-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26: 1320-32.
7. Felton TW, HopeWW, Lomaestro BM et al. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother 2012; 56: 4087-94.
8. Kim MK, Capitano B, Mattoes HM et al. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillintazobactam. Pharmacotherapy 2002; 22: 569-77.
9. Leary R, Jelliffe R, Schumitzky A et al. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings of the Fourteenth IEEE Symposium on Computer-Based Medical Systems, Bethesda, MD, USA, 2001. p. 389-94. IEEE, Washington, DC, USA.
10. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles, CA: Biomedical Simulations Resource, 2009.
11. Rey E, Treluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35: 313-29.
12. Vinks AA, Den Hollander JG, Overbeek SE et al. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother 2003; 47: 541-7.
13. Bulitta JB, Duffull SB, Kinzig-SchippersMet al. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007; 51: 2497-507.
14. Smith AL, Fiel SB, Mayer-Hamblett N et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123: 1495-502.
15. Hurley MN, AriffAH, Bertenshaw C et al. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J Cyst Fibros 2012; 11: 288-92.
16. Falagas ME, Tansarli GS, Ikawa K et al. Clinical outcomes with extended or continuous versus short-termintravenous infusion of carbapenems and piperacillin/tazobactam: a systematic reviewand meta-analysis. Clin Infect Dis 2013; 56: 272-82.